Last updated 4 days ago

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

320 patients around the world

Available in Brazil

Apellis Pharmaceuticals, Inc.

1Research sites

320Patients around the world

This study is for people with

Renal disease

End-stage renal disease

Kidney Transplant

From 18 Years

All Gender

: Aged at least 18 years.
Have end-stage kidney disease and be on the waiting list for a kidney transplant from a deceased donor.
Be on dialysis at the time of your transplant and produce very little urine (less than 200 mL per day equivalent to ≤1 cup). You must have been on dialysis for at least 3 months.
Be receiving your first or second kidney transplant from a deceased donor.
It cannot be due to a serious infection or a serious blood clot in your previous transplant.
Your calculated Panel Reactive Antibody (CPRA) level must be below 50%.
Be getting a donor kidney that meets the study's specific requirements.
Be at low to medium risk of transplant rejection, and be scheduled to receive.
A medication called ATG as part of your transplant procedure.
Steroids (corticosteroids) as part of your treatment at the time of screening.
A medication called tacrolimus (or a similar drug) after your transplant, according to usual medical practice.
Have received certain vaccines before starting the study treatment, specifically.
Pneumococcal (S. pneumoniae).
Meningococcal (N. meningitidis types A, C, W, Y, and B).
Haemophilus influenzae type B.
If you haven't had these vaccines, you may still qualify to be part of the study, provided your doctor plans to administer preventive antibiotics until vaccination can be given per protocol, and with notification to the sponsor.

: Have taken part in another medical research study or used an experimental drug, treatment, or device in the past 30 days (or longer, depending on the drug).
Have recently used certain medications that affect the immune system, such as rituximab, belimumab, or other approved complement-blocking drugs.
Weigh less than 20kg or more than 120kg at screening.
Have or had recently had any of the following infections.
Hepatitis B or Hepatitis C (unless treated and no longer active).
HIV (human immunodeficiency virus) at any time.
Have had cancer in the past 5 years, unless it was.
A small, treated skin cancer (like basal or squamous cell).
A very small kidney cancer that was found early and treated.
Have received any other organ transplant (except for one previous kidney transplant), or are scheduled for a transplant involving more than one organ.

Hospital das Clínicas da Faculdade de Medicina da São Paulo - USP

Recruiting

Rua Dr. Ovídio Pires de Campos 785 - Estado de São Paulo 05403-000

SponsorApellis Pharmaceuticals, Inc.

Study typeInterventional

Conditions

End-stage renal diseaseKidney Transplant

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT07020832